Cerebro-1™ — An Investigational Lipid-Based Candidate for Cannabis Intoxication & CHS

Cerebro-1™ — An Investigational Lipid-Based Candidate for Cannabis Intoxication & CHS

A research-stage program exploring whether lipid-based approaches may offer a future pathway for addressing cannabis intoxication and Cannabinoid Hyperemesis Syndrome (CHS).

A rapid, safe infusion-based approach designed to reverse severe symptoms and shorten emergency department stays.

Cerebro-1 — Breakthrough Lipid-Sink Treatment for Cannabinoid Intoxication & CHS

A rapid, safe infusion-based approach designed to reverse severe symptoms and shorten emergency department stays.

About us

About us

About Us

Sanare Bioscience is committed to advancing research that addresses urgent and underserved public health needs. Our work spans lipid science, toxicology, cannabinoid-related emergencies, and community health challenges that continue to impact families, healthcare systems, and policymakers.
We operate at the intersection of scientific innovation and public health advocacy — partnering with clinicians, researchers, and community leaders to support responsible, evidence-based innovation.

Cerebro-1™ Research Program

Cerebro-1 is an investigational lipid-based candidate being studied for potential relevance to cannabis intoxication and CHS, two conditions contributing to rising emergency department visits across the U.S. and Canada.

Our research efforts focus on understanding lipid sequestration mechanisms, evaluating formulation characteristics, planning preclinical studies, and collaborating with experts in toxicology and emergency care.

RETEXO ™

RETEXO ™

Research Pipeline

Our research pipeline reflects ongoing development focused on lipid science, toxicology, and cannabinoid exposure-related emergencies. These efforts support foundational science that may inform future advancements in cannabinoid toxicity research.

Partner with Sanare

We collaborate with researchers, healthcare systems, advocacy organizations, and public health leaders who are committed to advancing responsible scientific development and awareness around cannabinoid-related emergencies.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.

We provide innovative solutions that work
to bridge gaps in the drug development business. 

Cerebro-1 is an investigational product candidate currently in early-stage development. It has not been evaluated or approved by the U.S. Food and Drug Administration (FDA). No safety or efficacy has been established. All information on this website is for educational and research-oriented purposes only and is not medical advice.

© 2024 Sanare Bioscience. All rights reserved.